**Listeria monocytogenes Ankle Osteomyelitis in a Patient with Rheumatoid Arthritis on Adalimumab: A Report and Literature Review of Listeria monocytogenes Osteomyelitis**

Takafumi Kubota¹,², Yuichiro Mori¹,³, Gen Yamada⁴, Ivor Cammack⁵, Toshiya Shinohara⁶, Suguru Matsuzaka¹ and Tetsuya Hoshi¹

**Abstract:** Localized *Listeria* infection predominantly occurs in the prosthetic and hip joints. We herein report a case of *Listeria monocytogenes* ankle osteomyelitis in a 73-year-old man receiving adalimumab who was transferred to our hospital because of suspected rheumatoid arthritis (RA) flare. He reported a four-month history of left ankle swelling. A surgical biopsy revealed *L. monocytogenes* osteomyelitis in the left tibia and talus bones. The patient was successfully treated with antibiotics and surgical debridement. Thus, infection due to *L. monocytogenes* can present as ankle osteomyelitis in immunocompromised patients and may mimic an RA flare.

**Key words:** *Listeria monocytogenes*, osteomyelitis, tumor necrosis factor (TNF)-alpha inhibitor, adalimumab, rheumatoid arthritis

(Intern Med 60: 3171-3176, 2021) (DOI: 10.2169/internalmedicine.5633-20)

**Introduction**

Tumor necrosis factor (TNF)-alpha inhibitors are widely used to treat autoimmune diseases such as rheumatoid arthritis (RA), inflammatory bowel disease, ankylosing spondylitis, and psoriasis (1). Bacterial, mycobacterial, fungal or viral infections are a known, potentially serious adverse effect of these drugs. *Listeria monocytogenes* meningitis, sepsis, and septic arthritis in patients using TNF-alpha inhibitors have been reported, but little is known about *L. monocytogenes* ankle osteomyelitis associated with adalimumab treatment (1-4).

We herein summarize and compare eight *L. monocytogenes* osteomyelitis cases from the literature with our own case.

**Case Report**

A 73-year-old man with a 15-year history of RA was transferred to our hospital for the assessment of a possible RA flare. His medical history included suspected tuberculous lymphadenitis, ischemic heart disease, and dyslipidemia but no pneumocystis pneumonia or cytomegalovirus infection. He exhibited left ankle swelling for 4 months and gait difficulties due to pain but no diarrhea. He was administered 40 mg of adalimumab every 2 weeks for 7 months. In addition, his RA was controlled with methylprednisolone (8 mg/day) and iguratimod (50 mg/day). His diet comprised pasteurized milk and cheese daily and only common raw foods, such as vegetables and fish, consumed in Japan.

On an examination, the patient’s vital signs were normal. He had a well-defined 4-cm mass superficial to the medial malleolus of his left ankle. The mass was not tender or...
erythematous, but mild limitation of range of motion in the left ankle joint and pain during walking were observed. The remaining examination findings were normal.

Blood tests showed an elevated white blood cell count (16.7×10^3/μL; neutrophils 81%, lymphocytes 7%, monocytes 7%, eosinophils 1%, and basophils 0%) and C-reactive protein (CRP) (17.6 mg/dL). Plain radiographs suggested granulation of the left tibia and talus bones (Fig. 1). Magnetic resonance imaging (MRI) showed a decreased T1 signal in the tibia and talus and granulation and increased fat-suppressed T2 signal in the tibia, talus, and granulation (Fig. 1). Blood cultures were repeatedly negative. Based on his use of the immunosuppressants and history of suspected tuberculous lymphadenitis, we initially suspected tuberculosis osteomyelitis and thus discontinued the adalimumab and iguratimod treatments. To make a definite diagnosis, surgical biopsies of the distal tibia, talus, and mass in the ankle were performed, and their culture revealed the presence of \textit{L. monocytogenes}. A pathological examination revealed neutrophilic infiltration in the adjacent bone and synovial membrane (Fig. 2) and \textit{L. monocytogenes} abscess in the mass. There were no signs of caseating epithelioid granulomas. An analysis of the synovial fluid was culture-negative.

We diagnosed him with \textit{L. monocytogenes} osteomyelitis and initiated intravenous ampicillin (2 g, 6 hours) and gentamicin (90 mg, 8 hours) on day 14. On day 24, the affected bone was resected, and cement fixation was performed. Gentamicin was discontinued on day 29 (duration: 16 days). His initial erythrocyte sedimentation rate (ESR) after admission was 109 mm/h on day 29. As the symptoms improved with the removal of the infected bone and the ESR decreased to 40 mm/h, which were considered in previous reports to meet the criteria for osteomyelitis being cured or antibiotics being terminated (5-7), ampicillin treatment was discontinued on day 80 (duration: 66 days). We performed a second operation on day 143 to remove the cement and transplant autogenous iliac bone graft as a substitute (Fig. 3). He slowly recovered completely, and his gait returned to normal. There has been no recurrence of infection for three years.

\section*{Discussion}

Our case indicates that \textit{L. monocytogenes} infection can
increase the risk of L. monocytogenes infection, treated using adalimumab and may mimic an RA flare.

L. monocytogenes ankle osteomyelitis is a rare manifestation. L. monocytogenes is a small, aerobic, Gram-positive, non-encapsulated bacillus that can cause central nervous system infection, sepsis, and gastroenteritis (8-10). In certain cases, L. monocytogenes causes localized infections (8-10). Among the 43 retrospective cases studied, L. monocytogenes joint and bone infections mainly occurred in the hip (60%) and prosthetic joints (84%) (11). L. monocytogenes osteomyelitis is even rarer, and only 10 cases have been reported (11-18). Patient characteristics were not described in two cases (11). We have summarized the distribution of infection in our case along with that in the other eight cases in Table (12-18). There were four spinal infections-two in the tibia, one in the femur, and one in the proximal phalanx-in addition to the infection in the tibia and talus in our case (12-18). Only one patient had a prosthetic joint (12). Our patient and six others had underlying or predisposing conditions, such as leukemia in two cases, diabetes mellitus in two cases, and RA in one case (12-16). The mean age was 67.8±13.7 years old (12-18). Our patient and two others reported an intake of dairy products (13, 17). Three patients in total (including ours) were undergoing immunosuppressive therapy (12, 14).

L. monocytogenes ankle osteomyelitis can occur in patients at a high risk for L. monocytogenes infection and undergoing adalimumab treatment. Reported risk factors for L. monocytogenes infection include pregnancy, old age, immunocompromising conditions, malignancy, immunosuppressive therapy, and dairy product consumption (19, 20). Even in pasteurized milk, post-pasteurization contamination and the probable survival of L. monocytogenes are known to cause infections (21, 22). They inhibit the activation and differentiation of macrophages and phagosome formation, which play important roles in the clearance of intracellular pathogens, such as Mycobacterium tuberculosis and L. monocytogenes (1). The incidence rate of L. monocytogenes infection in patients with RA treated using TNF-alpha inhibitors is 0.27-0.30 per 1,000 patient-years, which is 75 times greater than that observed in the general population (23, 24). Among TNF-alpha inhibitors, adalimumab and infliximab have a higher risk of infection due to M. tuberculosis than etanercept (24). Nevertheless, whether there is increased risk of L. monocytogenes osteomyelitis from adalimumab over other TNF-alpha antagonists is not known. Furthermore, although osteomyelitis was not observed, the risk of septic arthritis in patients with RA treated using TNF-alpha inhibitors was highest in the early months of therapy (25). In fact, our case developed the symptoms three months after starting adalimumab. In contrast, the risk of infection increases with longer steroid use (26). Similarly, our case had been treated for RA for 15 years. In addition, our patient may have had arthritis owing to the possibility of a false-negative L. monocytogenes osteomyelitis in the joint fluid culture and the findings of synovial inflammation.

In addition, L. monocytogenes osteomyelitis can mimic an RA flare and hence may be misdiagnosed in patients with RA. The symptoms of an RA flare closely resemble those of osteomyelitis in terms of the expression of a fever, fatigue, pain, and swelling (27, 28). Based on our case and previously published cases, 44.4% (4/9) of the patients experienced pain or swelling involving the hand or foot. However, there are some indications to help differentiate between these two presentations. For example, RA flares may be prone to occur rapidly and typically resolve within one to two weeks, but L. monocytogenes osteomyelitis may tend to present insidiously (12-16, 27-29). Among 43 cases of L. monocytogenes joint and bone infections, 73% were subacute or chronic in their onset, developing over more than 7 days (11). In our case comparison, 66.7% (6/9) of cases also presented with a subacute or chronic onset, and the mean duration from the onset to a hospital visit was 53.4±55.6 days (12-18). In addition, Listeria infection tends to involve a single bone compared with an RA flare (12-18, 27-29). As mentioned in the previous paragraph, a detailed medical history to evaluate the risk factors for Listeria infection may prove helpful (4, 19, 20, 23). Some diagnostic tests are also important to differentiate between the two conditions. However, non-specific markers of inflammation tend to be found in both conditions, as the ESR and CRP are elevated in both Listeria infection and RA, and the ferritin changes in infection or non-infectious inflammation have not been well determined owing to inconsistent findings among studies (30, 31). Nevertheless, the following findings in imaging studies are helpful for diagnosing osteomyelitis: 1) MRI findings of extensive and intense bone marrow changes (32-34) and 2) ultrasound findings of subcutaneous edema, subcutaneous power Doppler signal changes, and periosteal vascularity (35). Finally, a biopsy is crucial for the final diagnosis. In fact, in our patient, the medical history,
Table. Characteristics of Patients with Listeria Monocytogenes Osteomyelitis.

| Case [Ref] | Age | Sex | Co-morbidities | Pregnancy | Food consumption | Immunosuppressant | Prosthetic joint involvement | Chief complaint | Duration of symptoms | Location | Culture | Treatment | Antibiotic therapy | Response to treatment |
|------------|-----|-----|----------------|-----------|------------------|------------------|--------------------------|----------------|---------------------|-----------|---------|-----------|-------------------|---------------------|
| 1 [12]    | 57  | M   | DM, asthma     | (-)       | NA               | Corticosteroid   | (-)                      | Progressive back pain   | 3 weeks           | T5       | NA      | (+)       | Ampicillin and tobramycin | At follow-up six months after completion of therapy, the patient was well and without evidence of recurrent infection. |
| 2 [12]    | 70  | M   | Total hip replacement, previous Listeria bacteremia, mitral valve replacement, previous rheumatic heart disease | (-)       | NA               | NA               | (+)                      | Right hip pain          | 5 months           | Rt.Hip  | (-)    | (+)       | Ampicillin and tobramycin | The patient remained free of complaints for seven months after hospital discharge. |
| 3 [13]    | 69  | M   | Previous spinal laminectomy | (-)       | Pate and unpasteurized cheeses | NA               | (-)                      | Back pain               | 5 months           | L5-S1    | (-)    | NA       | Epidural abscess | NA               |
| 4 [14]    | 54  | F   | Acute lymphoblastic leukemia | (-)       | NA               | 6-mercaptopurine cyclophosphamide methotrexate | (-)                      | Right lower leg pain, fever, rigors, erythema 8 cm x 3 cm over the lower third of her right tibia | 2 days             | Rt. Tibia | (+)   | NA       | Vancomycin and ceftriaxone | The pain gradually subsided over the subsequent six weeks of treatment and the patient became asymptomatic. |
| 5 [16]    | 43  | M   | Chorionic lymphoblastic leukemia | (-)       | NA               | NA               | (-)                      | Painful swelling of the left 4th finger | 1 month           | Lt. 4th proximal phalanx | (+) | Aspiration of the swollen area (+) | The left 4th finger improved over the six weeks of treatment and showed minimal swelling without pain or tenderness. |
| 6 [12]    | 74  | F   | DM, HTN, Obesity, CKD and chronic venous insufficiency | (-)       | NA               | NA               | (-)                      | Left ankle pain | 10 days           | Lt. Talus | NA      | (+)       | Ampicillin for 1 month => oral ciprofloxacin | The patient was well when he was discharged from the hospital after one month of ampicillin treatment. |
| 7 [17]    | 92  | M   | HTN, HF, arrhythmia, gastric ulcer, and hip arthroplasty | (-)       | Raw milk and raw cheese | None | (-)                      | Fever and acute lower back pain | 1 week           | Lt. L4-S1 | (+)  | NA       | Amoxicillin for 6 days and gentamicin for 4 days => oral ceftriaxone for 3 months | At the three-month clinical assessment, the patient had been recovering slowly and regaining mobility. |
| 8 [18]    | 79  | M   | Bilateral hernia repair with mesh, bilateral subclavian to carotid artery bypass and repair of an endovascular infrarenal abdominal aortic aneurysm, HTN, dyslipidemia, gout, reflux, smoker | (-)       | No consumption of processed meats, cheeses or other dairy products. | None | (-)                      | Acute, progressively worsening right-sided back pain radiating to the right groin and anterior thigh | 3 weeks           | L3-L4    | (+)   | (-)   | Ampicillin for 6 weeks | The patient rapidly improved over the treatment. The patient was subsequently seen in follow-up at 2- and 6-month time points with on-going clinical recovery and no recurrence of disease. |
| 9 [Present] | 73  | M   | RA | (-) | Pasteurized milk and cheese | Corticosteroid, adalimumab, and iginatimod | (-)                      | Left ankle swelling | 4 months           | Lt. Tibia and talus | (-) | (+) | Lt. Ankle joint aspiration | Gentamicin for 3 weeks and ampicillin for 14 weeks | The patient slowly made a complete recovery and his gait returned to normal. There has been no recurrence of his infection for three years. |

Ref: reference number, DM: diabetes mellitus, HTN: hypertension, CKD: chronic kidney disease, RA: rheumatoid arthritis, HF: heart failure, NA: not available, (+): positive, (-): negative
MRI results, and biopsy findings greatly contributed to the final diagnosis. In conclusion, L. monocytogenes osteomyelitis in the ankle can occur in patients with RA receiving adalimumab and may mimic an RA flare. Since TNF-alpha inhibitors are widely used, it is important to consider checking for infection, including L. monocytogenes, in patients presenting with joint or bone pain. Further research is necessary to determine whether or not such missed infections may be more common than previously considered.

The authors state that they have no Conflict of Interest (COI).

Acknowledgement

We express our sincere thanks to Dr. Akane Fukuda for supporting the data collection.

References

1. Ali T, Bronze, Kaitha, Mahmoud, Ftaisi, Stone. Clinical use of anti-TNF therapy and increased risk of infections. Drug Healthc Patient Saf 5: 79-99, 2013.
2. Schett G, Herak P, Graninger W, Smolen JS, Aringer M. Listeria-associated arthritis in a patient undergoing etanercept therapy: Case report and review of the literature. J Clin Microbiol 43: 2537-2541, 2005.
3. FDA Drug Safety Communication: Drug labels for the Tumor Necrosis Factor - alpha (TNFα) blockers now include warnings about infection with Legionella and Listeria bacteria Facts about TNFα blockers. 2011 [Internet]. [cited 2020 May 1]. Available from: http://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-drug-labels-tumor-necrosis-factor-alpha-tnfα-blockers-nw-now-include.
4. Bodro M, Paterson DL. Listeriosis in patients receiving biologic therapies. 32: 1225-1230, 2013.
5. Michail M, Jude E, Liaskos C, et al. The performance of serum inflammatory markers for the diagnosis and follow-up of patients with osteomyelitis. Int J Low Extrem Wounds 12: 94-99, 2013.
6. Lipsky BA, Berendt AR, Cornia PB, et al. 2012 infectious diseases society of America clinical practice guideline for the diagnosis and treatment of diabetic foot infections. Clin Infect Dis 54: 132-173, 2012.
7. Lazzarini L, Lipsky BA, Mader JT. Antibiotic treatment of osteomyelitis: What have we learned from 30 years of clinical trials? Int J Infect Dis 9: 127-138, 2005.
8. Doganay M. Listeriosis: clinical presentation. FEMS Immunol Med Microbiol 35: 173-175, 2003.
9. Alterberger F, Wagner M. Listeriosis: a resurgent foodborne infection. Clin Microbiol Infect 16: 16-23, 2010.
10. Gellin BG, Broome C V. Listeriosis. J Am Med Assoc 261: 1313-1320, 2019.
11. Charlier C, Leclercq A, Cazenave B, et al. Listeria monocytogenes-associated joint and bone infections: a study of 43 consecutive cases. Clin Infect Dis 54: 240-248, 2012.
12. Chirgwin K, Gleich S. Listeria monocytogenes osteomyelitis. Arch Intern Med 149: 931-932, 1989.
13. Khan KM, Pao W, Kendler J. Epidural abscess and vertebral osteomyelitis caused by Listeria monocytogenes: case report and literature review. Scand J Infect Dis 33: 714-716, 2001.
14. Houang ET, Williams CJ, Wrigley PFM. Acute Listeria monocytogenes osteomyelitis. 4: 113-114, 1976.
15. Louthenoo W, Schumacher HR. Listeria monocytogenes osteomyelitis complicating leukemia: report and literature review of listeria osteoarticular infections. Journal of Rheumatology 17: 107-110, 1990.
16. Fernández De Orueta L, Esteban Fernández J, Aichner HFI, Casillas Villamor Á. Listeria monocytogenes osteomyelitis. Med Clin (Barc) 139: 7753, 2012.
17. Aubin GG, Bouteille D, Bourcier R, et al. Unusual case of spondyloleidiscitis due to Listeria monocytogenes. J Bone Jt Infect 1: 7-9, 2016.
18. Al Ohaly R, Ranganath N, Saffie MG, Shroff A. Listeria spondyloleidiscitis: an uncommon etiology of a common condition; a case report. BMC Infect Dis 20: 4-7, 2020.
19. Goulet V, Hebert M, Hedberg C, et al. Incidence of listeriosis and related mortality among groups at risk of acquiring listeriosis. Clin Infect Dis 54: 652-660, 2012.
20. Silk BJ, Mahon BE, Griffin PM, et al. Vital signs: Listeria illnesses, deaths, and outbreaks - United States, 2009-2011. Morb Mortal Wkly Rep 62: 448-452, 2013.
21. Hanson H, Whitfield Y, Lee C, et al. Listeria monocytogenes associated with pasteurized chocolate milk, Ontario, Canada. Emerg Infect Dis 25: 581-584, 2019.
22. Fleming DW, Cochi SL, MacDonald KL, et al. Pasteurized milk as a vehicle of infection in an outbreak of listeriosis. N Engl J Med 299: 690-694, 1978.
23. Peña-Sagredo JL, Hernández M V, Fernandez-Llanio N, et al. Listeria monocytogenes infection in patients with rheumatic diseases on TNF-alpha antagonist therapy: The Spanish Study Group experience. Clin Exp Rheumatol 26: 854-859, 2008.
24. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Rates of serious infection, including site-specific and bacterial intracranial infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 54: 2368-2376, 2006.
25. Galloway JB, Hyrich KL, Mercer LK, et al. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70: 1810-1814, 2011.
26. Dixon WG, Abramowicz M, Beauchamp ME, et al. Immediate and delayed impact of oral glucocorticoid therapy on risk of serious infection in older patients with rheumatoid arthritis: a nested case-control analysis. Ann Rheum Dis 71: 1128-1133, 2012.
27. Hewlett S, Sanderson T, May J, et al. “I’m hurting, I want to kill myself”: rheumatoid arthritis flare is more than a high joint count—an international patient perspective on flare where medical help is sought. Rheumatology 51: 69-76, 2012.
28. Berthelot JM, De Bandt M, Morel J, et al. A tool to identify recent or present rheumatoid arthritis flare from both patient and physician perspectives: The “FLARE” instrument. Ann Rheum Dis 71: 1110-1116, 2012.
29. Bykver VP, Shadick N, Frits M, et al. Flares in rheumatoid arthritis: Frequency and management. A report from the BRASS registry. J Rheumatol 41: 227-234, 2014.
30. Kim SE, Kim UJ, Jang MO, et al. Diagnostic use of serum ferritin levels to differentiate infectious and noninfectious diseases in patients with fever of unknown origin. Dis Markers 34: 211-218, 2013.
31. Seyhan H, Sabuncu MN, Sabuncu GE, Akar N. The correlation between ferritin level and acute phase parameters in rheumatoid arthritis and systemic lupus erythematosus. Eur J Rheumatol 1: 92-95, 2014.
32. Narváez JA, Narváez J, Roca Y, Aguilera C. MR imaging assessment of clinical problems in rheumatoid arthritis. Eur Radiol 12: 1819-1828, 2002.
33. Horino T, Ichii O, Terada Y. Suppurative osteomyelitis incorrectly diagnosed as rheumatoid arthritis. J Clin Rheumatol 26: E261-E263, 2020.
34. Karchevsky M, Schweitzer ME, Morrison WB, Parellada JA. MRI
findings of septic arthritis and associated osteomyelitis in adults.
Am J Roentgenol **182**: 119-122, 2004.

35. Lu CH, Hsiao YF, Hsu HC, et al. Can ultrasound differentiate acute erosive arthritis associated with osteomyelitis, rheumatoid arthritis, or gouty arthritis? Int J Rheum Dis **22**: 1972-1977, 2019.